ALPS Advisors’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $293K | Sell |
21,949
-7,787
| -26% | -$104K | ﹤0.01% | 940 |
|
|
2025
Q1 | $303K | Sell |
29,736
-3,020
| -9% | -$30.8K | ﹤0.01% | 895 |
|
|
2024
Q4 | $519K | Buy |
32,756
+4,851
| +17% | +$76.8K | ﹤0.01% | 598 |
|
|
2024
Q3 | $1.62M | Sell |
27,905
-239
| -0.8% | -$13.9K | 0.01% | 390 |
|
|
2024
Q2 | $1.29M | Buy |
28,144
+2,766
| +11% | +$126K | 0.01% | 412 |
|
|
2024
Q1 | $1.68M | Buy |
25,378
+5,766
| +29% | +$382K | 0.01% | 380 |
|
|
2023
Q4 | $780K | Sell |
19,612
-2,281
| -10% | -$90.7K | 0.01% | 538 |
|
|
2023
Q3 | $698K | Buy |
21,893
+149
| +0.7% | +$4.75K | 0.01% | 553 |
|
|
2023
Q2 | $874K | Buy |
21,744
+2,939
| +16% | +$118K | 0.01% | 518 |
|
|
2023
Q1 | $803K | Buy |
18,805
+118
| +0.6% | +$5.04K | 0.01% | 512 |
|
|
2022
Q4 | $897K | Buy |
18,687
+4,665
| +33% | +$224K | 0.01% | 503 |
|
|
2022
Q3 | $528K | Sell |
14,022
-240
| -2% | -$9.04K | 0.01% | 580 |
|
|
2022
Q2 | $394K | Sell |
14,262
-10,409
| -42% | -$288K | ﹤0.01% | 655 |
|
|
2022
Q1 | $1.34M | Sell |
24,671
-2,400
| -9% | -$131K | 0.01% | 280 |
|
|
2021
Q4 | $1.58M | Sell |
27,071
-1,528
| -5% | -$89.4K | 0.02% | 314 |
|
|
2021
Q3 | $1.13M | Sell |
28,599
-2,088
| -7% | -$82.6K | 0.01% | 379 |
|
|
2021
Q2 | $1.3M | Buy |
+30,687
| New | +$1.3M | 0.01% | 375 |
|